US20150119331A1 - Use of Histones for Therapeutic Purposes - Google Patents

Use of Histones for Therapeutic Purposes Download PDF

Info

Publication number
US20150119331A1
US20150119331A1 US14/588,836 US201514588836A US2015119331A1 US 20150119331 A1 US20150119331 A1 US 20150119331A1 US 201514588836 A US201514588836 A US 201514588836A US 2015119331 A1 US2015119331 A1 US 2015119331A1
Authority
US
United States
Prior art keywords
histone
thrombocytopenia
administration
patient
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/588,836
Inventor
Michael Zeppezauer
Reiner Class
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie
Original Assignee
Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie filed Critical Symbiotec GmbH Gesellschaft zur Forschung und Entwicklung der Biotechnologie
Priority to US14/588,836 priority Critical patent/US20150119331A1/en
Publication of US20150119331A1 publication Critical patent/US20150119331A1/en
Assigned to SYMBIOTEC GENELLSCHAFT ZUR ERFORSCHUNG AUF DEM GEIBEIT DER BIOTECHNOLOGIE, MBH reassignment SYMBIOTEC GENELLSCHAFT ZUR ERFORSCHUNG AUF DEM GEIBEIT DER BIOTECHNOLOGIE, MBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CLASS, REINER, ZEPPEZAUER, MICHAEL
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the invention relates to the use of at least one human recombinant histone of H 1 subtype and/or of its therapeutically effective segment, especially histone H1.3 for therapeutic purposes.
  • CFU-S hematopoietical stem cells
  • thrombocytopenia In complex pathological conditions such as acute myeloid leukemia, there is frequently observed to be a thrombocytopenia which may even be enhanced by a chemotherapeutic treatment of the leukemia. Thrombocytopenia is, however, also observed with other etiology. Since thrombocytopenia may lead to life-threatening internal hemorrhages, therapies for various pathological symptoms which may be the cause of the thrombocytopenia are frequently made particularly difficult.
  • FIG. 1 shows the effect of the active substances of the invention in a 0.9% NaCl solution at, 37.5 mg/qm 2 of body surface area on the thrombocytopenia of a patient.
  • the active substance of the invention shows on the one hand a positive result in the treatment of a hematological disorder such as leukemia, but on the other hand also a positive result in the treatment of the thrombocytopenia associated with the hematological disorders.
  • the active substance used in this case based on human recombinant H1.3 concentrations 37.5 mg/qm 2 of body surface area etc., having been administered in a 0.9% NaCl solution intravenously 3 times a week over a period of about 4 hours.
  • FIG. 1 shows the effect of the active substances of the invention in a 0.9% NaCl solution at, 37.5 mg/qm 2 of body surface area on the thrombocytopenia of a patient.
  • the platelets in peripheral blood are on the ordinate in a number of from 0 to 40 ⁇ 10 9 .
  • Treatment with active substance of the invention for three weeks is shown on the abscissa, the platelet count measured for the patient before the first treatment being greatly reduced at about 8 ⁇ 10 9 .
  • three drip infusions take place per week with in each case 4 hours per infusion, with the 1st to 3rd infusion on the 1st, 3rd and 5th day in the first week, with the 4th to 6th infusion on the 8th, 10th and 12th day in the second week and finally with the 7th to 9th infusion on the 15th, 17th and 19th day in the 3rd week.
  • FIG. 1 shows at the start of the second week up to conclusion of the treatment in the third week a jump in the platelet count after the 5th day of treatment and then a continuous rise in the platelet count from the 8th to the subsequent 19th day of treatment and a further slower rise in the platelet count at the first control examination on the 29th day and at a later discharge day FU1 of the patient without further addition of the active substance of the invention, the finally measured platelet count being, as already stated, about 32.5 ⁇ 10 9 .
  • the invention is not restricted to the use of human recombinant H1.3. Because of the close relationship of the H1 subtypes, it is obvious to a skilled worker also to employ as active substance other human recombinant H1 subtypes as basis for the active substance of the invention.
  • the active substance of the invention preferably consists of the complete unshortened subtypes of histone proteins.
  • the therapeutically effective segment of which he is capable directly on the basis of his expert knowledge and experience without outstanding innovative contributions being necessary in this case.
  • Such therapeutically effective histone segments therefore lie within the range of equivalents of the teaching of the invention disclosed herein.
  • the invention further discloses the therapeutic teaching of employing, when there is a threatening or incipient primary disorder which, experience has shown, may result in thrombocytopenia, the active substance of the invention prophylactically against a threatening thrombocytopenia even if, unlike leukemia, the active substance of the invention is not effective against the primary disorder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.

Description

  • The present application is a continuation of U.S. patent application Ser. No. 13/758,950 filed Feb. 4, 2013, which is a continuation of U.S. patent application Ser. No. 11/920,050; filed Nov. 6, 2008 now abandoned, which is a national stage entry of PCT/EP2006/004167; filed May 4, 2006, which claims priority to DE 10 2005 022 319.2; filed May 10, 2005, all which are hereby incorporated by reference.
  • The invention relates to the use of at least one human recombinant histone of H1 subtype and/or of its therapeutically effective segment, especially histone H1.3 for therapeutic purposes.
  • The use of therapeutic active substances based on human recombinant histone H1 subtypes for the treatment of cancers, e.g. leukemia, is disclosed in the article by Reiner Class et al. in Am. J. Clin. Oncol. (CCT) vol. 19 No. 5 1996 and European patent application 98919254.7.
  • The effect of histone H1 and H2A/H2B fractions from calf thymus on hematopoietical stem cells (CFU-S) in normal and radioactively irradiated rats was described in a Russian article by Semina 0. V. et al. in Radiatsionnaia Biologiia, Radioecologiia 34 (4-5), 1994, July-October.
  • In complex pathological conditions such as acute myeloid leukemia, there is frequently observed to be a thrombocytopenia which may even be enhanced by a chemotherapeutic treatment of the leukemia. Thrombocytopenia is, however, also observed with other etiology. Since thrombocytopenia may lead to life-threatening internal hemorrhages, therapies for various pathological symptoms which may be the cause of the thrombocytopenia are frequently made particularly difficult.
  • It was therefore an object of the invention to find an active substance which can be used therapeutically for thrombocytopenia in order thus also to improve substantially the success of curing the basic symptom as inducer of the thrombocytopenia.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 (hereinafter “FIG. 1”) shows the effect of the active substances of the invention in a 0.9% NaCl solution at, 37.5 mg/qm2 of body surface area on the thrombocytopenia of a patient.
    •  DETAILED DESCRIPTION
  • It has been possible according to the invention to achieve the object by using for the therapy of thrombocytopenia inter alia as a result of faulty stem cell differentiation or weakened proliferation of megakaryocytes an active substance based on at least one human recombinant histone (especially at least one histone of H1 subtype) and/or its therapeutically effective segment.
  • This applies especially to a thrombocytopenia as concomitant manifestation of a hematological disorder.
  • It is moreover possible to employ the therapeutic method of the invention for the treatment of thrombocytopenia during or after chemotherapy for the treatment of a hematological disorder, especially acute myeloid leukemia.
  • It has surprisingly been possible to show that the active substance of the invention shows on the one hand a positive result in the treatment of a hematological disorder such as leukemia, but on the other hand also a positive result in the treatment of the thrombocytopenia associated with the hematological disorders.
  • It was thus possible with one and the same active substance to note both a regression in the leukemia and an increase in platelets.
  • It was possible to achieve therapeutic trial results also on patients with human recombinant histone H1.3, it having been possible to reduce markedly the number of pathological tumor cells in an AML patient and, at the same time, to increase substantially platelet production, whereby it was possible to improve substantially the prospects of curing the patient.
  • The trial results are reproduced in more detail below, the active substance used in this case, based on human recombinant H1.3 concentrations 37.5 mg/qm2 of body surface area etc., having been administered in a 0.9% NaCl solution intravenously 3 times a week over a period of about 4 hours.
  • FIG. 1 shows the effect of the active substances of the invention in a 0.9% NaCl solution at, 37.5 mg/qm2 of body surface area on the thrombocytopenia of a patient.
  • The platelets in peripheral blood are on the ordinate in a number of from 0 to 40×109. Treatment with active substance of the invention for three weeks is shown on the abscissa, the platelet count measured for the patient before the first treatment being greatly reduced at about 8×109. Then in each case three drip infusions take place per week with in each case 4 hours per infusion, with the 1st to 3rd infusion on the 1st, 3rd and 5th day in the first week, with the 4th to 6th infusion on the 8th, 10th and 12th day in the second week and finally with the 7th to 9th infusion on the 15th, 17th and 19th day in the 3rd week. On the 29th day after the first infusion, a control measurement of the platelet count took place without a further infusion with the active substance of the invention. At a later time FU1, the patient was discharged with an almost normal platelet count of about 34×109, without an active substance of the invention having been supplied even once. This value lay outside the need to supply stored blood. The patient was asked to attend a follow-up examination with the possibility of resumption of treatment if the platelet count has not improved further on its own or had even deteriorated. The results of the follow-up examination are not shown here.
  • The appended FIG. 1 shows at the start of the second week up to conclusion of the treatment in the third week a jump in the platelet count after the 5th day of treatment and then a continuous rise in the platelet count from the 8th to the subsequent 19th day of treatment and a further slower rise in the platelet count at the first control examination on the 29th day and at a later discharge day FU1 of the patient without further addition of the active substance of the invention, the finally measured platelet count being, as already stated, about 32.5×109.
  • The invention is not restricted to the use of human recombinant H1.3. Because of the close relationship of the H1 subtypes, it is obvious to a skilled worker also to employ as active substance other human recombinant H1 subtypes as basis for the active substance of the invention.
  • Following the successful therapy of patients with a thrombocytopenia, here as concomitant syndrome of an AML leukemia, with human recombinant histone H1.3, it is particularly obvious to a skilled worker also to employ other recombinant H1 subtypes as alternative active substances singly or in combination according to the invention.
  • The active substance of the invention preferably consists of the complete unshortened subtypes of histone proteins. However, it is also obvious to a skilled worker to look for the therapeutically effective segment, of which he is capable directly on the basis of his expert knowledge and experience without outstanding innovative contributions being necessary in this case. Such therapeutically effective histone segments therefore lie within the range of equivalents of the teaching of the invention disclosed herein.
  • The invention further discloses the therapeutic teaching of employing, when there is a threatening or incipient primary disorder which, experience has shown, may result in thrombocytopenia, the active substance of the invention prophylactically against a threatening thrombocytopenia even if, unlike leukemia, the active substance of the invention is not effective against the primary disorder.

Claims (21)

1-7. (canceled)
8. A method for treating thrombocytopenia in a patient in need thereof, the method comprising: administering to the patient at least three doses of a pharmaceutical composition comprising histone H1.3 or a therapeutically active histone H1.3 segment during a period of at least 8 days, wherein administration of the pharmaceutical composition increases the number of platelets in the peripheral blood, thereby treating the thrombocytopenia.
9. The method according to claim 8, wherein the thrombocytopenia results from a hematological disorder.
10. The method according to claim 9, wherein the hematological disorder is a leukemia.
11. The method according to claim 10, wherein the leukemia is an acute myeloid leukemia.
12. The method according to claim 8, wherein the treatment of the thrombocytopenia occurs concurrently with or after a therapy for a hematological disorder.
13. The method according to claim 12, wherein the therapy is a chemotherapy.
14. The method according to claim 12, wherein the hematological disorder is a leukemia.
15. The method according to claim 14, wherein the leukemia is an acute myeloid leukemia.
16. The method according to claim 8, wherein the administration is intravenous.
17. The method according to claim 8, further comprising the administration of other human recombinant subtypes of histone H1 in combination with the histone H1.3 or therapeutically active histone H1.3 segment.
18. A method for treating thrombocytopenia in a patient in need thereof caused by a primary disorder, comprising: administering to the patient a pharmaceutical composition comprising histone H1.3 or a therapeutically active histone H1.3 segment, wherein the histone H1.3 is not effective to treat the primary disorder.
19. The method according to claim 18, wherein the thrombocytopenia results from a hematological disorder.
20. The method according to claim 18, wherein the treatment of the thrombocytopenia occurs concurrently with or after a therapy for a hematological disorder.
21. The method according to claim 20, wherein the therapy is a chemotherapy.
22. The method according to claim 18, wherein administration to the patient is administration of at least three doses of a pharmaceutical composition comprising histone H1.3 or a therapeutically active histone H1.3 segment during a period of at least 8 days.
23. The method according to claim 18, wherein the administration is intravenous.
24. The method according to claim 18, further comprising the administration of other human recombinant subtypes of histone H1 in combination with the histone H1.3 or therapeutically active histone H1.3 segment.
25. A method for treating threatening or incipient thrombocytopenia in a patient which is expected to be caused by chemotherapy, comprising: administering to the patient a pharmaceutical composition comprising histone H1.3 or a therapeutically active histone H1.3 segment concurrently with chemotherapy.
26. The method according to claim 25, wherein the administration is intravenous.
27. The method according to claim 25, further comprising the administration of other human recombinant subtypes of histone H1 in combination with the histone H1.3 or therapeutically active histone H1.3 segment.
US14/588,836 2005-05-10 2015-01-02 Use of Histones for Therapeutic Purposes Abandoned US20150119331A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/588,836 US20150119331A1 (en) 2005-05-10 2015-01-02 Use of Histones for Therapeutic Purposes

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE102005022319.2 2005-05-10
DE102005022319A DE102005022319A1 (en) 2005-05-10 2005-05-10 Use of histones for therapeutic purposes
EPPCT/EP06/04167 2006-05-04
PCT/EP2006/004167 WO2006119912A2 (en) 2005-05-10 2006-05-04 Use of histones for therapeutic purposes
US92005008A 2008-11-06 2008-11-06
US13/758,950 US8962562B2 (en) 2005-05-10 2013-02-04 Use of histones for therapeutic purposes
US14/588,836 US20150119331A1 (en) 2005-05-10 2015-01-02 Use of Histones for Therapeutic Purposes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/758,950 Continuation US8962562B2 (en) 2005-05-10 2013-02-04 Use of histones for therapeutic purposes

Publications (1)

Publication Number Publication Date
US20150119331A1 true US20150119331A1 (en) 2015-04-30

Family

ID=37310925

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/920,050 Abandoned US20090305966A1 (en) 2005-05-10 2006-05-04 Use of histones for therapeutic purposes
US13/758,950 Expired - Fee Related US8962562B2 (en) 2005-05-10 2013-02-04 Use of histones for therapeutic purposes
US14/588,836 Abandoned US20150119331A1 (en) 2005-05-10 2015-01-02 Use of Histones for Therapeutic Purposes

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/920,050 Abandoned US20090305966A1 (en) 2005-05-10 2006-05-04 Use of histones for therapeutic purposes
US13/758,950 Expired - Fee Related US8962562B2 (en) 2005-05-10 2013-02-04 Use of histones for therapeutic purposes

Country Status (12)

Country Link
US (3) US20090305966A1 (en)
EP (1) EP1879609B1 (en)
JP (2) JP2008540473A (en)
KR (3) KR20140137462A (en)
CN (1) CN101171027A (en)
CA (2) CA2608019C (en)
DE (1) DE102005022319A1 (en)
ES (1) ES2461564T3 (en)
HU (1) HUE027070T2 (en)
PL (1) PL1879609T3 (en)
PT (1) PT1879609E (en)
WO (1) WO2006119912A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005022319A1 (en) * 2005-05-10 2006-11-23 Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh Use of histones for therapeutic purposes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902146B2 (en) * 1997-04-11 2011-03-08 Michael Zeppezauer Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties
US8962562B2 (en) * 2005-05-10 2015-02-24 Lipoxen Technologies Incorporated Use of histones for therapeutic purposes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818763A (en) * 1984-01-12 1989-04-04 Volker Rusch Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes
EP0347057A1 (en) 1988-05-31 1989-12-20 Schering Biotech Corporation Method of treating myeloid leukemias
DE4000154A1 (en) * 1990-01-04 1991-07-11 Symbiotec Gmbh CHEMOTHERAPEUTIC AGENT, IN PARTICULAR FOR TREATING CANCER DISEASES
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
DE19715149A1 (en) 1997-04-11 1998-10-15 Symbiotec Gmbh Cancer therapeutic and diagnosis for the characterization of cancer cells with individual properties
US6884423B1 (en) * 1998-08-13 2005-04-26 Symbiotec Gmbh Antimicrobial histone H1 compositions, kits, and methods of use thereof
AU4676500A (en) * 1999-04-28 2000-11-10 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus
DE10001113A1 (en) * 2000-01-13 2001-07-26 Strathmann Ag & Co Recombinant human histone protein, useful e.g. as anticancer or antibiotic agent, expressed in prokaryotic cells
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
ATE481977T1 (en) 2001-02-22 2010-10-15 Philadelphia Health & Educatio COMPOSITIONS FOR PREVENTING THROMBOCYTE AGGREGATION
JP2002355048A (en) * 2001-05-31 2002-12-10 Communication Research Laboratory Ribonucleotide reductase r1 and peptide inhibiting the same
DE10230223A1 (en) * 2002-07-04 2004-01-22 Tegenero Ag Microparticles with CD28-specific monoclonal antibodies
US20040146585A1 (en) * 2002-10-31 2004-07-29 Oregon Health & Science University Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902146B2 (en) * 1997-04-11 2011-03-08 Michael Zeppezauer Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties
US8962562B2 (en) * 2005-05-10 2015-02-24 Lipoxen Technologies Incorporated Use of histones for therapeutic purposes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cines et al., 2009, Semin. Hematol. 46:S2-14 *
Tfayli et al., www.medscape.org/viewarticle/569207, released January 28, 2008, Management of Thrombocytopenia in Patients with Leukemia, Medscape Oncology *
www.cancer.gov/cancertopics/pdq/treatment/CLL/healthprofessional/page2, accessed 6/2014, "Chronic Lymphocytic Leukemia Treatment, Stage Information for Chronic Lymphocytic Leukemia" *

Also Published As

Publication number Publication date
PT1879609E (en) 2014-06-09
ES2461564T3 (en) 2014-05-20
JP2013151573A (en) 2013-08-08
CA2608019A1 (en) 2006-11-16
WO2006119912A3 (en) 2007-04-12
US8962562B2 (en) 2015-02-24
EP1879609B1 (en) 2014-03-12
JP2008540473A (en) 2008-11-20
KR20080007351A (en) 2008-01-18
KR20140137462A (en) 2014-12-02
DE102005022319A1 (en) 2006-11-23
WO2006119912A2 (en) 2006-11-16
PL1879609T3 (en) 2014-08-29
CA2608019C (en) 2013-07-02
US20140148391A1 (en) 2014-05-29
CA2811995A1 (en) 2006-11-16
EP1879609A2 (en) 2008-01-23
JP5667238B2 (en) 2015-02-12
HUE027070T2 (en) 2016-08-29
US20090305966A1 (en) 2009-12-10
KR20130099207A (en) 2013-09-05
CN101171027A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
Reglodi et al. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat
US6899883B2 (en) Treatment of diabetes
EA201270292A1 (en) THERAPY GLATIRAMER ACETATE WITH LOW CIRCUIT
US5432176A (en) Method of retarding the progression of chronic renal failure
EP4008337A1 (en) Synergistic effect of cobra neurotoxin polypeptide on inhibiting opioid hyperalgesia and tolerance and alleviating pain associated therewith
EP1369119A1 (en) Il-12 expression controlling agents
RU2009118962A (en) APPLICATION OF IL-1 ANTAGONISTS FOR TREATMENT OF GHIT AND PSEUDOGRAPHY
JP2009524612A (en) Method for treating and / or preventing multiple sclerosis and use of erythropoietin for the manufacture of a medicament for intermittent treatment and / or intermittent prevention of multiple sclerosis
US8962562B2 (en) Use of histones for therapeutic purposes
US5378686A (en) Therapeutic treatment of fibromyalgia
EP0804185B1 (en) Arsenic medicaments for the treatment of chronic fatigue syndrome
US6716835B1 (en) Use of diltiazem for treating retinal pathologies
CA2543507A1 (en) Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
EP0942749A2 (en) Treatment of stress-induced skin disease by corticotropin releasing hormone antagonists and skin mast cell degranulation inhibitors
EP0669824B1 (en) Use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension
CN1822850A (en) Treatment or prevention of damage due to radiation exposure.
US11351229B2 (en) Combination therapies for treating infantile spasms and other treatment resistant epilepsies
AU706088B2 (en) Transferrin compositions to alleviate the side effects of cytotoxic drugs
JP7265804B2 (en) Use of Recombinant Proteins for Treatment of Metabolic Disorders
Wang et al. Protective effects and mechanisms of dexmedetomidine on cerebral ischemia reperfusion injuries in rats
WO2023154412A9 (en) Anti-inflammatory compounds, pharmaceutical compositions, and treatment methods
EP0663211A1 (en) Agent for preventing and treating digestive mucosal disorders

Legal Events

Date Code Title Description
AS Assignment

Owner name: SYMBIOTEC GENELLSCHAFT ZUR ERFORSCHUNG AUF DEM GEI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZEPPEZAUER, MICHAEL;CLASS, REINER;SIGNING DATES FROM 20071106 TO 20071107;REEL/FRAME:039122/0977

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE